Compare GSK plc (GSK) vs Marvell Technology Inc (MRVL) Price & Performance

GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.

The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.

Marvell Technology (MRVL) trades at $275.28, down 3.3% in the last session, but maintains strong technical momentum with bullish moving averages and support at $267. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center products comprising 74% of sales. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $327.86 price target, representing 19% upside potential.

Marvell's AI-driven growth story appears compelling with custom chip deals with hyperscalers potentially generating $120 billion in cumulative revenue. However, high valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) present risks. The stock's 210% YTD gain suggests much optimism is priced in, requiring continued execution on the $18 billion fiscal 2028 revenue guidance to justify current levels.